Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis

Samson, Sandrine I.; Leventhal, Phillip S.; Salamand, Camille; Meng, Yao; Seet, Bruce T.; Landolfi, Victoria; Greenberg, David; Hollingsworth, Rosalind

doi:10.1080/14760584.2019.1575734

Cited by 30 publications

(25 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As for panel A, the titer values and decay rates are hypothetical. However, the range of titers seen in an immunization cohort is consistent with published data ( 103 , 133 , 134 ); an ∼50-fold decrease in the SARS-CoV-1 NAb titer during a 6-month period was measured in RBD-immunized mice ( 62 ), and NAb titers induced by a MERS-CoV DNA vaccine in humans had declined by ∼50-fold within a year ( 103 ).…”

Section: Longevity and Protective Capacity Of Antibody Responses To Csupporting

confidence: 88%

“…3 ). Typically, antibody titers vary by well more than 100-fold among people given HIV-1 or influenza virus protein vaccines ( 82 , 133 , 134 ). Antibody responses, neutralizing or not, to SARS-CoV-1 and -2 and MERS-CoV S-protein-based vaccines are similarly variable in animals and humans ( 35 , 62 , 88 , 92 , 93 , 103 ).…”

Section: What Is a Protective Antibody Titer For A Sars-cov-2 Vaccinementioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds

Moore

Klasse

2020

J Virol

134

View full text Add to dashboard Cite

In this review, we address issues that relate to the rapid “Warp Speed” development of vaccines to counter the COVID-19 pandemic. We review the antibody response that is triggered by SARS-CoV-2 infection of humans, and how it may inform vaccine research. The isolation and properties of neutralizing monoclonal antibodies from COVID-19 patients provide additional information on what vaccines should try to elicit. The nature and longevity of the antibody response to coronaviruses are relevant to the potency and duration of vaccine-induced immunity. We summarize the immunogenicity of leading vaccine candidates tested to date in animals and humans, and discuss the outcome and interpretation of virus-challenge experiments in animals. By far the most immunogenic vaccine candidates for antibody responses are recombinant proteins, which are not included in the initial wave of “Warp Speed” immunogens. A substantial concern for SARS-CoV-2 vaccines is adverse events, which we review by considering what was seen in studies of SARS-CoV-1 and MERS-CoV vaccines. We conclude by outlining the possible outcomes of the “Warp Speed” vaccine program, which range from the hoped-for rapid success to a catastrophic adverse influence on vaccine uptake generally.

show abstract

Section: Longevity and Protective Capacity Of Antibody Responses To Csupporting

confidence: 88%

Section: What Is a Protective Antibody Titer For A Sars-cov-2 Vaccinementioning

confidence: 99%

COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds

Moore

Klasse

2020

J Virol

134

View full text Add to dashboard Cite

show abstract

“…A meta-analysis of five randomized trials indicated a reduced frequency of a composite indicator of cardiovascular events in vaccinated subjects vs. control subjects (risk ratio, 0.64 [95% CI: 0.48, 0.86]) [42] . A randomized phase III trial of a high-dose influenza vaccine in approximately 32,000 subjects ≥ 65 years of age showed that it is more immunogenic and efficacious than a standard-dose vaccine in this population [43] , [44] . In addition, it further reduced serious cardio-respiratory events by 17.7% (95% CI: 6.6, 27.4%; from 35.5 to 26.8 events per 1000 participant-seasons), pneumonia events by 39.8% (95% CI: 19.3, 55.1%; from 7.4 to 4.4 events per 1000 participant-seasons), and congestive heart failure by 24.0% (95% CI: −7.2, 46.1%; from 4.7 to 3.6 events per 1000 participant-seasons) [45] .…”

Section: Cardiovascular Diseasementioning

confidence: 99%

The disease burden of influenza beyond respiratory illness

Macías

McElhaney

Chaves

et al. 2021

Vaccine

Self Cite

175

120

View full text Add to dashboard Cite

Although influenza is primarily considered a respiratory infection and causes significant respiratory mortality, evidence suggests that influenza has an additional burden due to broader consequences of the illness. Some of these broader consequences include cardiovascular events, exacerbations of chronic underlying conditions, increased susceptibility to secondary bacterial infections, functional decline, and poor pregnancy outcomes, all of which may lead to an increased risk for hospitalization and death. Although it is methodologically difficult to measure these impacts, epidemiological and interventional study designs have evolved over recent decades to better take them into account. Recognizing these broader consequences of influenza virus infection is essential to determine the full burden of influenza among different subpopulations and the value of preventive approaches. In this review, we outline the main influenza complications and societal impacts beyond the classical respiratory symptoms of the disease.

show abstract

“…In our community studies of the response to influenza vaccination in older adults, using the same 40-item Frailty Index, older adults on average have a Frailty Index of 0.1 (Non-frail are < 0.1) (unpublished observations). A systematic review of high-dose relative to standard-dose influenza vaccine trials, showed that the better antibody responses to high-dose influenza vaccine was independent of sex, age > 75 years old, frailty, and chronic conditions [52]. This is supported by individual studies from Singapore [53], Germany [49], and the U.S. [54], all of which reported that frailty did not have a significant effect on antibody titres following standard dose vaccination in adults 60 and over.…”

Section: Impact Of Frailty On Outcomes Of Influenzamentioning

confidence: 99%

The immune response to influenza in older humans: beyond immune senescence

et al. 2020

View full text Add to dashboard Cite

Despite widespread influenza vaccination programs, influenza remains a major cause of morbidity and mortality in older adults. Age-related changes in multiple aspects of the adaptive immune response to influenza have been well-documented including a decline in antibody responses to influenza vaccination and changes in the cellmediated response associated with immune senescence. This review will focus on T cell responses to influenza and influenza vaccination in older adults, and how increasing frailty or coexistence of multiple (≥2) chronic conditions contributes to the loss of vaccine effectiveness for the prevention of hospitalization. Further, dysregulation of the production of pro-and anti-inflammatory mediators contributes to a decline in the generation of an effective CD8 T cell response needed to clear influenza virus from the lungs. Current influenza vaccines provide only a weak stimulus to this arm of the adaptive immune response and rely on re-stimulation of CD8 T cell memory related to prior exposure to influenza virus. Efforts to improve vaccine effectiveness in older adults will be fruitless until CD8 responses take center stage.

show abstract

Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis

Cited by 30 publications

References 60 publications

COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds

COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds

The disease burden of influenza beyond respiratory illness

The immune response to influenza in older humans: beyond immune senescence

Contact Info

Product

Resources

About